1
|
Buckland B, Sanyal G, Ranheim T, Pollard D, Searles JA, Behrens S, Pluschkell S, Josefsberg J, Roberts CJ. Vaccine process technology-A decade of progress. Biotechnol Bioeng 2024; 121:2604-2635. [PMID: 38711222 DOI: 10.1002/bit.28703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 03/04/2024] [Accepted: 03/14/2024] [Indexed: 05/08/2024]
Abstract
In the past decade, new approaches to the discovery and development of vaccines have transformed the field. Advances during the COVID-19 pandemic allowed the production of billions of vaccine doses per year using novel platforms such as messenger RNA and viral vectors. Improvements in the analytical toolbox, equipment, and bioprocess technology have made it possible to achieve both unprecedented speed in vaccine development and scale of vaccine manufacturing. Macromolecular structure-function characterization technologies, combined with improved modeling and data analysis, enable quantitative evaluation of vaccine formulations at single-particle resolution and guided design of vaccine drug substances and drug products. These advances play a major role in precise assessment of critical quality attributes of vaccines delivered by newer platforms. Innovations in label-free and immunoassay technologies aid in the characterization of antigenic sites and the development of robust in vitro potency assays. These methods, along with molecular techniques such as next-generation sequencing, will accelerate characterization and release of vaccines delivered by all platforms. Process analytical technologies for real-time monitoring and optimization of process steps enable the implementation of quality-by-design principles and faster release of vaccine products. In the next decade, the field of vaccine discovery and development will continue to advance, bringing together new technologies, methods, and platforms to improve human health.
Collapse
Affiliation(s)
- Barry Buckland
- National Institute for Innovation in Manufacturing Biopharmaceuticals, University of Delaware, Newark, Delaware, USA
| | - Gautam Sanyal
- Vaccine Analytics, LLC, Kendall Park, New Jersey, USA
| | - Todd Ranheim
- Advanced Analytics Core, Resilience, Chapel Hill, North Carolina, USA
| | - David Pollard
- Sartorius, Corporate Research, Marlborough, Massachusetts, USA
| | | | - Sue Behrens
- Engineering and Biopharmaceutical Processing, Keck Graduate Institute, Claremont, California, USA
| | - Stefanie Pluschkell
- National Institute for Innovation in Manufacturing Biopharmaceuticals, University of Delaware, Newark, Delaware, USA
| | - Jessica Josefsberg
- Merck & Co., Inc., Process Research & Development, Rahway, New Jersey, USA
| | - Christopher J Roberts
- National Institute for Innovation in Manufacturing Biopharmaceuticals, University of Delaware, Newark, Delaware, USA
| |
Collapse
|
2
|
Li Z, Zhao H, Gao X, Sun F, Liu S, Zhang Z, Zhai X, Cao Y, Wu Y, Lin G. Novel envelope protein time-resolved fluoroimmunoassay as an alternative in vitro potency assay for quality control of inactivated Japanese encephalitis virus vaccine. Heliyon 2024; 10:e33015. [PMID: 39027461 PMCID: PMC11254517 DOI: 10.1016/j.heliyon.2024.e33015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Revised: 04/22/2024] [Accepted: 06/12/2024] [Indexed: 07/20/2024] Open
Abstract
Japanese encephalitis (JE) vaccination is the most effective way to prevent JE. Plaque reduction neutralization test (PRNT) as the standard method for potency testing for inactivated JE vaccine could not provide the exact potency value. Envelope (E) protein of JE virus induces the body to create neutralizing antibodies. There is a potential for using the determination of E protein to assess the immunogenicity and efficacy of JE vaccine. In this study, an automatic time-resolved fluoroimmunoassay for detection of E protein in JE vaccine was established as a simple and rapid in vitro potency assay to complement PRNT, including the expression and paired screening of monoclonal antibodies, the establishment of assay method and performance verification. A pair of anti-E protein neutralizing antibodies (L022 and L034) were screened to construct the sandwich detection pattern. After pre-treating the vaccine sample, the entire analysis was performed using a fully automated machine, which had a little detection time and eliminated manual error. The results of the validation experiment met the requirements for quality control. The linear range was from 0.78125 U/mL to 25 U/mL, the sensitivity was 0.01 U/mL, the intra-assay coefficient of variation was less than 5 %, and the inter-assay coefficient of variation was less than 10 %. The recovery from the dilution was between 90 % and 110 %. This present TRFIA shown good stability and effectiveness in quality control for samples related to JE vaccine production. The outcomes demonstrated that the present TRFIA could be an alternative in vitro potency assay in quality control for inactivated JE vaccine.
Collapse
Affiliation(s)
- Zhaoyue Li
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Hui Zhao
- Department of Plastic and Aesthetic Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Xuzhe Gao
- Liaoning Cheng Da Biotechnology Co., Ltd., Shenyang, China
| | - Feifei Sun
- Liaoning Cheng Da Biotechnology Co., Ltd., Shenyang, China
| | - Shiyuan Liu
- Liaoning Cheng Da Biotechnology Co., Ltd., Shenyang, China
| | - Zhigao Zhang
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Xiangming Zhai
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Yue Cao
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Yingsong Wu
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Guanfeng Lin
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| |
Collapse
|
3
|
Li Q, Yan R, Bai N, Tan Z, Yu Q, Su H, Wei X, Li A, Chen X, Li Z, He Y, Li H, Li X, Mao Y. Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells. Int J Med Sci 2023; 20:1282-1292. [PMID: 37786447 PMCID: PMC10542018 DOI: 10.7150/ijms.87134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 08/02/2023] [Indexed: 10/04/2023] Open
Abstract
Rabies continues to be a huge threat to public health. The rabies virus envelope glycoprotein (RABV G) is a major rabies virus antigen and contains neutralizing epitopes, which are primary candidates for subunit vaccines and diagnostic antigens. However, the production and purification of rRABV G while retaining its antigenic and immunogenic remains to be a challenge. Here, we aimed to establish a platform for rRABV G production and purification, and determine the immunogenicity and antigenicity of rRABV G. The cDNA fragment encoding the soluble form of RABV G was synthesized and cloned into a lentiviral expressing vector. Recombinant lentiviral vector LV-CMV-RABV G-eGFP was packaged, titered, and then transduced into HEK 293T cells. The cell culture supernatant was purified using nickel affinity chromatography and subsequently confirmed through Western Blot analysis and indirect enzyme-linked immunosorbent assay (ELISA). The ELISA utilized human sera obtained from individuals who had been vaccinated with the human commercial Purified Vero Cells Rabies Vaccine (PVRV). Notably, we observed a neutralizing antibody response in immunized pigs rather than in mice. This discrepancy could potentially be attributed to factors such as the instability of the rRABV G protein, variations in host responses, and variances in the adjuvant used. Taking all these findings into account, the rRABV G protein generated in this study exhibits promise as a potential vaccine candidate for the prevention of rabies.
Collapse
Affiliation(s)
- Qingqing Li
- Clinical Laboratory, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, 528000, China
- School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China
| | - Renhe Yan
- Guangzhou Bioneeds Biotechnology CO., LTD, Guangzhou, 510000, China
| | - Na Bai
- Department of Nuclear Medicine, Yuxi People's Hospital of Yunnan Province,Yuxi, 653100, China
| | - Zhenglan Tan
- Clinical Laboratory, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, 528000, China
| | - Qing Yu
- Clinical Laboratory, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, 528000, China
| | - Heng Su
- Clinical Laboratory, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, 528000, China
| | - Xiwen Wei
- Clinical Laboratory, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, 528000, China
| | - Andrew Li
- Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, 21205, USA
| | - Xueji Chen
- South China Institute of Biomedicine, Guangzhou, 510000, China
| | - Zhenyu Li
- School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China
| | - Yuezhong He
- South China Institute of Biomedicine, Guangzhou, 510000, China
| | - Hongwei Li
- School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, China
| | - Xiangxin Li
- Clinical Laboratory, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, 528000, China
| | - Yingying Mao
- South China Institute of Biomedicine, Guangzhou, 510000, China
| |
Collapse
|
4
|
Li Z, Wu M, Chen Y, Li Y, Zhang Z, Zhai X, Cao Y, Li X, Yang Y, Wu Y, Lin G. A time-resolved fluorescence immunoassay for rapid and precise automatic quality control of human papillomavirus type 68 VLPs in human papillomavirus vaccine. J Immunol Methods 2023:113518. [PMID: 37385433 DOI: 10.1016/j.jim.2023.113518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 06/18/2023] [Accepted: 06/26/2023] [Indexed: 07/01/2023]
Abstract
The effectiveness and necessity of human papillomavirus (HPV) vaccination to prevent HPV infection and cervical cancer are increasingly recognized by people. The 15-valent HPV vaccine, which protects against almost high-risk types of HPV viruses identified by WHO, has attracted much attention. However, as the valence of vaccines increases, quality control in the HPV vaccine production process is facing more challenges. The precise quality control of the HPV type 68 virus-like particles (VLPs), one of the unique components of the 15-valent HPV vaccine that distinguishes it from existing vaccines, is the new requirement for vaccine manufacturers. Here we developed a novel time-resolved fluorescence immunoassay (TRFIA) for rapid and precise automatic quality control of HPV68 VLPs in HPV vaccine. Two murine monoclonal antibodies specifically targeting the HPV68 L1 protein were used to establish a classical sandwich assay. Except for pretreating the vaccine sample, the whole analysis process was performed by a fully automated machine, which saves detection time and gets rid of manual error. Multiple experiments established that the current novel TRFIA can efficiently and reliably analyses HPV68 VLPs. Present novel TRFIA has exhibited merits with speed, robustness, high sensitivity with a minimum detection value of 0.08 ng/mL, considerable accuracy, a wide detection range (up to 1000 ng/mL) and excellent specificity. It is also expected to provide a new detection method for quality control for each HPV type VLPs. To summarize, the novel TRFIA is of great interest for application in HPV vaccine quality control.
Collapse
Affiliation(s)
- Zhaoyue Li
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Muhan Wu
- School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China
| | - Yin Chen
- Liaoning Cheng Da Biotechnology Co., Ltd., Shenyang, China
| | - Yang Li
- Liaoning Cheng Da Biotechnology Co., Ltd., Shenyang, China
| | - Zhigao Zhang
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Xiangming Zhai
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Yue Cao
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Xijiu Li
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Yiqi Yang
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Yingsong Wu
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| | - Guanfeng Lin
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| |
Collapse
|
5
|
Yang Y, Li Z, Zhang Z, Zhai X, Li X, Cao Y, Fang H, He C, Wu Y, Lin G. A custom-made time-resolved fluoroimmunoassay for the quantitation of the host cell protein of Vero in rabies vaccine. J Virol Methods 2023; 318:114752. [PMID: 37209780 DOI: 10.1016/j.jviromet.2023.114752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 05/16/2023] [Accepted: 05/17/2023] [Indexed: 05/22/2023]
Abstract
Host cell proteins (HCPs) are the process-specific and inevitable impurities during the manufacture via a host cell, which affect the safety or efficacy of the bio-product. However, the commercial HCP enzyme-linked immunosorbent assay (ELISA) kits may not apply to specific products such as rabies vaccine from Vero cells. More advanced and process-specific assay methods are needed in the quality control of rabies vaccine throughout the whole manufacturing process. Therefore, a novel time-resolved fluoroimmunoassay (TRFIA) for the detection of process-specific HCP of Vero cells in rabies vaccine was established in this study. Liquid chromatography coupled tandem mass spectrometry (LC-MS/MS) was used during the preparation of HCP antigen. Based on a sandwich-type immunoassay format, analytes in samples were captured by one antibody coating in the wells and "sandwiched" by another antibody labeled with europium chelates. Due to the complex composition of HCP, both the capture and detected antibodies are polyclonal antibodies from the same anti-HCP antibodies pool. Multiple experiments have identified the optimal conditions to allow the valid and reliable detection of HCP in rabies vaccine. The TRFIA had a satisfactory limit of detection value (0.011μg/ml) under optimal conditions, with the linear range from 0.0375 - 2.4μg/ml of HCP. The coefficient variations (CVs) were all < 10%, and the recoveries were in the range of 97.00% to 102.42%. All the test results of Vero cell protein reference substance were included in the expected concentration, which demonstrated that the present method was available for the test of HCP in rabies vaccine. Based on these results, the novel TRFIA to detect HCP appears to be important for application in modern vaccine quality control during the whole manufacturing process.
Collapse
Affiliation(s)
- Yiqi Yang
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| | - Zhaoyue Li
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| | - Zhigao Zhang
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| | - Xiangming Zhai
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| | - Xijiu Li
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| | - Yue Cao
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| | - Haolin Fang
- Guangzhou Baiyunshan Biologics Co., Ltd, No.1 Wanbao North Street, Panyu District, Guangzhou, China.
| | - Chunhui He
- Guangzhou Baiyunshan Biologics Co., Ltd, No.1 Wanbao North Street, Panyu District, Guangzhou, China.
| | - Yingsong Wu
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China; Correspondence to: Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| | - Guanfeng Lin
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China; Correspondence to: Experimental Center of Teaching and Scientific Research, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| |
Collapse
|
6
|
Sreenan B, Lee B, Wan L, Zeng R, Zhao J, Zhu X. Review of Mn-Doped Semiconductor Nanocrystals for Time-Resolved Luminescence Biosensing/Imaging. ACS APPLIED NANO MATERIALS 2022; 5:17413-17435. [PMID: 36874078 PMCID: PMC9980291 DOI: 10.1021/acsanm.2c04337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Colloidal semiconductor nanocrystals (NCs) have been developed for decades and are widely applied in biosensing/imaging. However, their biosensing/imaging applications are mainly based on luminescence-intensity measurement, which suffers from autofluorescence in complex biological samples and thus limits the biosensing/imaging sensitivities. It is expected for these NCs to be further developed to gain luminescence features that can overcome sample autofluorescence. On the other hand, time-resolved luminescence measurement utilizing long-lived-luminescence probes is an efficient technique to eliminate short-lived autofluorescence of samples while recording time-resolved luminescence of the probes for signal measurement after pulsed excitation from a light source. Despite time-resolved measurement being very sensitive, the optical limitations of many of the current long-lived-luminescence probes cause time-resolved measurement to be generally performed in laboratories with bulky and costly instruments. In order to apply highly sensitive time-resolved measurement for in-field or point-of-care (POC) testing, it is essential to develop probes possessing high brightness, low-energy (visible-light) excitation, and long lifetimes of up to milliseconds. Such desired optical features can significantly simplify the design criteria of time-resolved measurement instruments and facilitate the development of low-cost, compact, sensitive instruments for in-field or POC testing. Mn-doped NCs have recently been in rapid development and provide a strategy to solve the challenges faced by both colloidal semiconductor NCs and time-resolved luminescence measurement. In this review, we outline the major achievements in the development of Mn-doped binary and multinary NCs, with emphasis on their synthesis approaches and luminescence mechanisms. Specifically, we demonstrate how researchers approached these obstacles to achieve the aforementioned desired optical properties on the basis of the progressive understanding of Mn emission mechanisms. Afterward, we review representative applications of Mn-doped NCs in time-resolved luminescence biosensing/imaging and present the potential of Mn-doped NCs in advancing time-resolved luminescence biosensing/imaging for in-field or POC testing.
Collapse
Affiliation(s)
- Benjamin Sreenan
- Department of Electrical and Biomedical Engineering, University of Nevada-Reno, Reno, Nevada 89557, United States
| | - Bryan Lee
- Department of Electrical and Biomedical Engineering, University of Nevada-Reno, Reno, Nevada 89557, United States
| | - Li Wan
- Department of Physics, Wenzhou University, Wenzhou 325035, China
| | - Ruosheng Zeng
- School of Physical Science and Technology, Guangxi University, Nanning 530004, China
| | - Jialong Zhao
- School of Physical Science and Technology, Guangxi University, Nanning 530004, China
| | - Xiaoshan Zhu
- Department of Electrical and Biomedical Engineering, University of Nevada-Reno, Reno, Nevada 89557, United States
| |
Collapse
|
7
|
Ma H, Mao Q, Zhu Y, Cong C, Zheng S, Zhang Q, Chen C, Li L. Time-resolved fluorescence immunoassay (TRFIA) for the simultaneous detection of hs-CRP and lipoprotein(a) in serum. Biotechnol Appl Biochem 2022; 69:2617-2623. [PMID: 34981870 DOI: 10.1002/bab.2310] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Accepted: 12/27/2021] [Indexed: 12/27/2022]
Abstract
Elevated serum high-sensitivity C-reactive protein (hs-CRP) and lipoprotein(a) (Lp(a)) levels are associated with the development of native coronary atherosclerosis. We aimed to establish a new method for the simultaneous detection of hs-CRP and Lp(a) to predict the development of atherosclerosis. A one-step time-resolved fluorescence immunoassay (TRFIA) with europium(III) (Eu3+ ) or samarium(III) (Sm3+ ) labels was established, and the performance of this TRFIA (in terms of sensitivity, specificity, accuracy, and cutoff values) was evaluated using clinical serum samples and compared with those of registered kits. The sensitivity was 0.052 μg/ml for hs-CRP and 0.64 μg/ml for Lp(a). The intra-assay and inter-assay cross-reactivities (CVs) were very low, ranging from 2.05% to 4.67% for hs-CRP and from 2.42% to 6.43% for Lp(a). The CVs were very low (<0.34% and <2.65%, respectively) with five interferents. Additionally, there was a high Pearson coefficient between the present TRFIA method and the registered kits (R2 = 0.9967 and 0.9906, respectively). These data indicate that this study developed a TRFIA method that can be used for the quantitative detection of hs-CRP and Lp(a) in serum with high sensitivity, specificity, and accuracy. This TRFIA provides a new method for predicting the development of atherosclerosis.
Collapse
Affiliation(s)
- Hongyan Ma
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, China
| | - Qian Mao
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, China
| | - Yanbin Zhu
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, China
| | - Chunli Cong
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, China
| | - Shiyu Zheng
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, China
| | - Qi Zhang
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, China
| | - Cuicui Chen
- Guangzhou Youdi Biotechnology Co., Ltd., Guangzhou, China
| | - Laiqing Li
- Guangzhou Youdi Biotechnology Co., Ltd., Guangzhou, China
| |
Collapse
|
8
|
Zhang Z, Zhang J, Dai S, Xu H. A new method for screening acute/chronic lymphocytic leukemia: dual-label time-resolved fluorescence immunoassay. BMC Biotechnol 2022; 22:27. [PMID: 36180909 PMCID: PMC9526263 DOI: 10.1186/s12896-022-00758-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 09/14/2022] [Indexed: 11/22/2022] Open
Abstract
Background Lymphocytic leukemia (LL) is a primary malignant tumor of hematopoietic tissue, which seriously affects the health of children and the elderly. The study aims to establish a new detection method for screening acute/chronic LL using time-resolved fluorescence immunoassay (TRFIA) via quantitative detection of S100 calcium binding protein A8 (S100A8) and leucine-rich alpha-2-glycoprotein 1 (LRG1) in serum.
Methods Here a sandwich TRFIA was optimized and established: Anti-S100A8/LRG1 caputre antibodies immobilized on 96-well plates captured S100A8/LRG1, and then banded together with the anti-S100A8/LRG1 detection antibodies labeled with Europium(III) (Eu3+)/samarium(III) (Sm3+) chelates. Finally time resolved fluorometry measured the fluorescence intensity.
Results The sensitivity of S100A8 was 1.15 ng/mL(LogY = 3.4027 + 0.4091 × LogX, R2 = 0.9828, P < 0.001, dynamic range: 2.1–10,000 ng/mL), and 3.2 ng/mL for LRG1 (LogY = 3.3009 + 0.4082 × LogX, R2 = 0.9748, P < 0.001, dynamic range: 4.0–10,000 ng/mL). The intra-assay and inter-assay CVs were low, ranging from 5.75% to 8.23% for S100A8 and 5.30% to 9.45% for LRG1 with high specificity and affinity in serum samples. Bland–Altman plots indicated TRFIA and ELISA kits have good agreement in clinical serum samples. Additionally, the cutoff values for S100A8 and LRG1 were 1849.18 ng/mL and 588.08 ng/mL, respectively. Conclusion The present TRFIA method could be used for the quantitative detection of S100A8 and LRG1 in serum, and it has high sensitivity, accuracy and specificity. Clinically, this TRFIA method could be suitable for screening of LL via the quantitative detection of S100A8 and LRG1.
Collapse
Affiliation(s)
- Zhen Zhang
- Department of Logistics Management, Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200444, China
| | - Jintao Zhang
- Department of Medical Intensive Care Unit, Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200444, China
| | - Shanshan Dai
- Department of Medical Engineering, Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang, 830000, China
| | - Hang Xu
- Department of Surgical Intensive Care Unit, Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No.1058, Huan Zhen Bei Rd, Shanghai, 200444, China.
| |
Collapse
|
9
|
Liu C, Chen C, Lai H, Liang H, Zhong S, Guo G, Wang L, Li L. A New Method for Early Screening of Gastric Cancer (G17 and CA724 Dual-Labeled Time-Resolved Fluorescence Immunoassay). COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE 2022; 2022:1704948. [PMID: 35912162 PMCID: PMC9328981 DOI: 10.1155/2022/1704948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 06/30/2022] [Accepted: 07/05/2022] [Indexed: 11/18/2022]
Abstract
Gastric carcinoma (GC) is one of the most common malignancies in the world with the great early screening challenges. The study is aimed at establishing a new detection method for early screening GC using time-resolved fluorescence immunoassay (TRFIA) via quantitative detection of gastrin-17 (G-17) and carbohydrate antigen 724 (CA724) in serum. Time-resolved analyzer measured the fluorescence intensity. The standards of G-17/CA724 were used for drawing the standard curve, which is used to calculate the concentration of G-17 and CA724 in serum sample. The sensitivity for G-17 was 0.54 pg/mL and for CA724 was 0.28 U/mL with a wide-range analyze concentration (0.1-1000) pg/mL or U/mL. The average recoveries ranged from 100.52% to 110.30% for G-17 and 103.02% to 116.00% for CA724. All CVs of the intra- and interassay were below 10% with high specificity. There was a high Pearson coefficient between this TRFIA method and the commercially available kits (Pearson r 0.9117 for G-17 and 0.9449 for CA724). Additionally, the cutoff value was 88.41 pg/mL and 5.47 U/mL for CA724 in health subjects. This study established a TRFIA method for simultaneous detection of the concentrations of G-17 and CA724 in serum, which provide a new method for sensitive, accurate, and specific early screening of gastric cancer.
Collapse
Affiliation(s)
- Chang Liu
- Heilongjiang Academy of Chinese Medicine Sciences, Harbin, 150036, China
| | - Cuicui Chen
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China
| | - Hongrui Lai
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China
| | - Huankun Liang
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China
| | - Shuhai Zhong
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China
| | - Guiling Guo
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China
| | - Lei Wang
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China
| | - Laiqing Li
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China
| |
Collapse
|
10
|
Ma HY, Mao Q, Zhu YB, Cong CL, Zheng SY, Zhang Q, Chen CC, Li LQ. Time-resolved Fluorescence Immunoassay (TRFIA) for the Simultaneous Detection of MMP-9 and Lp-PLA2 in Serum. J Fluoresc 2021; 31:1771-1777. [PMID: 34495467 DOI: 10.1007/s10895-021-02811-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Accepted: 08/27/2021] [Indexed: 11/28/2022]
Abstract
Currently, atherosclerosis accounts for the majority of cardiovascular morbidity and mortality worldwide, and predicting the stability of atherosclerotic plaque is the main method to prevent atherosclerotic death. This study aims to establish a dual-label time-resolved fluorescence immunoassay (TRFIA) of matrix metalloprotein-9 (MMP-9) and lipoprotein-associated phospholipaseA2 (Lp-PLA2) to predict atherosclerotic plaque stability. A dual-label TRFIA was introduced for the simultaneous quantification of MMP-9 and Lp-PLA2 using fluorescent lanthanide (Eu3+ and Sm3+) chelates. The performance (sensitivity, specificity, accuracy, precision and reference intervals in different subjects) of this TRFIA was evaluated and compared with commercial kit. The sensitivity of the TRFIA for MMP-9 was 0.85 ng/mL and for Lp-PLA2 was 0.68 ng/mL with high affinity and specificity. The average recoveries were 94.58% to 109.82%, and 104.32% to 109.26%, respectively. All intra- and inter-assay CVs ranged from 3.10% to 5.46%. For the normal subjects, the cutoff value was 160.70 ng/mL for MMP-9 and 183.73 ng/mL for LP-PLA2; for the subjects with stable plaque, the cutoff value was 181.98~309.22 ng/mL for MMP-9 and 194.73~337.89 ng/mL for LP-PLA2; for the subjects with unstable plaque, the cutoff value was 330.43 ng/mL for MMP-9 and 343.23 ng/mL for LP-PLA2. This TRFIA detection results agreed well with the results of commercial kit (R2=0.9567 and R2=0.9771, respectively) in clinical serum samples. The TRFIA developed has a wide detection range and good sensitivity for the high-throughput simultaneous detection of MMP-9 and Lp-PLA2 in serum, which provides a new method for predicting the stability of atherosclerotic plaque.
Collapse
Affiliation(s)
- Hong-Yan Ma
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, 132000, China
| | - Qian Mao
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, 132000, China
| | - Yan-Bin Zhu
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, 132000, China
| | - Chun-Li Cong
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, 132000, China
| | - Shi-Yu Zheng
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, 132000, China
| | - Qi Zhang
- Department of Cardiology, Beihua University Affiliated Hospital, Jilin, 132000, China
| | - Cui-Cui Chen
- Guangzhou Youdi Biotechnology Co., Ltd, Guangzhou, 510663, China
| | - Lai-Qing Li
- Guangzhou Youdi Biotechnology Co., Ltd, Guangzhou, 510663, China.
| |
Collapse
|
11
|
Chen C, Lai H, Liang H, He Y, Guo G, Li L. A New Method for Detection African Swine Fever Virus: Time-resolved Fluorescence Immunoassay. J Fluoresc 2021; 31:1291-1296. [PMID: 34075517 PMCID: PMC8169433 DOI: 10.1007/s10895-021-02754-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 05/20/2021] [Indexed: 12/19/2022]
Abstract
African swine fever (ASF) has severely influenced the swine industry of the whole world. Fast and accurate African swine fever virus (ASFV) antigen detection is very important for ASF prevention. This study aims to establish a new detection method for detection ASFV antigen using time-resolved fluorescence immunoassay (TRFIA) in the nose and mouth discharge. A double antibody sandwich TRFIA method was optimized and established. Recombinant P30 recombinant antigen was captured by its antibodies immobilized on 96-well plate, and then banded together with another detection antibodies labeled with Europium(III) (Eu3+) chelates, finally time-resolved analyzer measured the fluorescence intensity. The performance of this TRFIA (sensitivity, specificity and accuracy) was evaluated using the clinical samples and compared with the nucleic acid testing method. The sensitivity of this TRFIA was 0.015 ng/mL (dynamic range 0.24-500 ng/mL) with high specificity. The recovery ranged from 92.00 to 103.62 %, the inter-assay CVs ranged from 5.50 to 11.96 %, and the intra-assay CVs was between 5.20 and 10.53 %. Additionally, the cutoff value was 0.016. TRFIA took only 45 min to generate results, and its detection capability comparable to the nucleic acid detection. This study developed a TRFIA method that could be used for qualitative/quantitative detection of ASFV antigen in pigs nasal discharge, which has high sensitivity, specificity and accuracy. This TRFIA provides a new method for rapidly screening ASFV infection in pigs industry.
Collapse
Affiliation(s)
- Cuicui Chen
- Guangzhou Youdi Bio-technology Co., Ltd, Guangzhou, 510663, China
| | - Hongrui Lai
- Guangzhou Youdi Bio-technology Co., Ltd, Guangzhou, 510663, China
| | - Huankun Liang
- Guangzhou Youdi Bio-technology Co., Ltd, Guangzhou, 510663, China
| | - Ying He
- Guangzhou Youdi Bio-technology Co., Ltd, Guangzhou, 510663, China
| | - Guiling Guo
- Guangzhou Youdi Bio-technology Co., Ltd, Guangzhou, 510663, China
| | - Laiqing Li
- Guangzhou Youdi Bio-technology Co., Ltd, Guangzhou, 510663, China.
| |
Collapse
|
12
|
The fourth case of rabies caused by organ transplantation in China. BIOSAFETY AND HEALTH 2021. [DOI: 10.1016/j.bsheal.2020.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
13
|
Bian L, Zhao H, He C, Fang H, Chen Z, Lin L, Ye K, Wu Y, Lin G. A time-resolved fluoroimmunoassay for assessing rabies antibody titers in the sera of vaccinated human subjects. Biologicals 2020; 68:54-59. [PMID: 32868168 DOI: 10.1016/j.biologicals.2020.08.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 08/15/2020] [Accepted: 08/17/2020] [Indexed: 12/20/2022] Open
Abstract
Several studies have investigated the use of simple in vitro tests for the assessment of rabies antibody titers in serum samples from vaccinated human subjects, which would allow the effectiveness of rabies vaccination to be conveniently evaluated. To this end, a novel time-resolved fluoroimmunoassay (TRFIA) for the assessment of rabies antibody titers was established in this study for evaluating the effectiveness of protection against rabies. The TRFIA had a satisfactory limit of detection value (0.035 IU/mL) under optimal conditions. Additionally, the application of the TRFIA was demonstrated in 68 serum samples with satisfactory results. The coefficient variations (CVs) were all <10%, and the recoveries were in the range of 90-110%. The correlation coefficient of titer values obtained using the present TRFIA and the rapid fluorescent focus inhibition test (RFFIT) was 0.733, with a coincidence rate regarding the evaluation results (protected or not protected by vaccination) of 100%. The preliminary results confirmed that the TRFIA had a higher performance than an enzyme-linked immunosorbent assay (ELISA), and could potentially replace the ELISA. Based on these results, the novel TRFIA appears to be a convenient tool for the evaluation of rabies vaccination results based on serum samples from vaccinated human subjects.
Collapse
Affiliation(s)
- Lun Bian
- Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Hui Zhao
- Department of Plastic and Aesthetic Surgery, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
| | - Chunhui He
- Guangzhou Promise Biologics Co., Ltd, No. 1 Wanbao North Street, Panyu District, Guangzhou, Guangdong, China
| | - Haolin Fang
- Guangzhou Promise Biologics Co., Ltd, No. 1 Wanbao North Street, Panyu District, Guangzhou, Guangdong, China
| | - Zhenhua Chen
- Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Li Lin
- Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Ke Ye
- Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
| | - Yingsong Wu
- Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| | - Guanfeng Lin
- Experimental Center of Teaching and Scientific Research, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
| |
Collapse
|
14
|
Chen C, Liang H, Hu B, Ning B, Lai H, He Y, Guo G, Zhong S, Li L. Determination of parvovirus antigen in the vaccine using time-resolved fluorescence immunoassay. Biotechnol Appl Biochem 2020; 68:597-602. [PMID: 32533780 DOI: 10.1002/bab.1967] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 06/06/2020] [Indexed: 12/16/2022]
Abstract
As a highly contagious and potentially fatal disease of dogs, canine parvovirus type 2 (CPV-2) usually causes severe myocarditis and gastroenteritis, while vaccine injection has greatly reduced the incidence of CPV-2 diseases. However, there is currently a lack of simple and effective method for quantitative detection of CPV-2 in vaccine. Therefore, this study aims to prepare an accurate method to determine the CPV-2 antigen (CPV-2-Ag) in vaccine. Here, a sandwich time-resolved fluorescence immunoassay (TRFIA) was established and optimized. Anti-CPV-2 antibodies were immobilized on 96-well plates to capture CPV-2-Ag, and then bound together with the detection antibodies labeled with Europium(III) (Eu3+ ) chelates; finally, time-resolved fluorometry was employed to measure the fluorescence intensity. Vaccination was performed to evaluate the relationship between CPV-2-Ag concentration and antibody titer. The sensitivity is 1.15 mEU/mL (LogY = 1.524 + 0.8667 × LogX, R2 = 0.9933), and the average recovery is among 91.00% to 106.39% without cross-reactions with the other canine viral antigen. The correlation between ELISA assay and this method is up to 0.9861. And, there is high correlation between the CPV-2-Ag concentration and antibody titers (R2 = 0.9234). This immunoassay established has high sensitivity, accuracy, and specificity, which indicate that this method could be suitable for quantitative detection of CPV-2-Ag in vaccine evaluation.
Collapse
Affiliation(s)
- Cuicui Chen
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou, 510663, China
| | - Huankun Liang
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou, 510663, China
| | - Baoyu Hu
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou, 510663, China
| | - Bo Ning
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou, 510663, China
| | - Hongrui Lai
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou, 510663, China
| | - Ying He
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou, 510663, China
| | - Guiling Guo
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou, 510663, China
| | - Shuhai Zhong
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou, 510663, China
| | - Laiqing Li
- Guangzhou Youdi Bio-Technology Co., Ltd., Guangzhou, 510663, China
| |
Collapse
|
15
|
Du M, Yang Q, Liu W, Ding Y, Chen H, Hua X, Wang M. Development of immunoassays with high sensitivity for detecting imidacloprid in environment and agro-products using phage-borne peptides. THE SCIENCE OF THE TOTAL ENVIRONMENT 2020; 723:137909. [PMID: 32222498 DOI: 10.1016/j.scitotenv.2020.137909] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Revised: 02/22/2020] [Accepted: 03/11/2020] [Indexed: 06/10/2023]
Abstract
Imidacloprid is the most widely used neonicotinoid insecticide and has been reported to pose a threat to ecological security and human health. Therefore, simple-to-operate and highly sensitive methods for the detection of trace levels of imidacloprid are necessary. Here, we isolated two phage-borne peptides that compete with imidacloprid to bind the monoclonal antibody (mAb) 3D11 from phage display peptide libraries. A phage-enzyme-linked immunosorbent assay (P-ELISA) and two phage time-resolved fluoroimmunoassays (P-TRFIAs) for the detection of imidacloprid were developed using the phage-borne peptides as substitutes for chemically synthesized antigens. After systematic optimization, the half-maximum inhibition concentrations (IC50) of the P-ELISA, P-TRFIA-1, and P-TRFIA-2 were 0.067 ng mL-1, 0.085 ng mL-1, and 0.056 ng mL-1, respectively. Based on their IC50 values, the sensitivities of the P-ELISA and P-TRFIAs were more than four times greater than those of previous immunoassays. Additionally, the immunoassays showed satisfactory recovery in the detection of spiked samples and good correlation with high performance liquid chromatography (HPLC) for the detection of samples containing incurred residues.
Collapse
Affiliation(s)
- Mei Du
- College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China; State & Local Joint Engineering Research Center of Green Pesticide Invention and Application, Nanjing 210095, China
| | - Qian Yang
- College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China; State & Local Joint Engineering Research Center of Green Pesticide Invention and Application, Nanjing 210095, China
| | - Weimei Liu
- College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China; State & Local Joint Engineering Research Center of Green Pesticide Invention and Application, Nanjing 210095, China
| | - Yuan Ding
- College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China; State & Local Joint Engineering Research Center of Green Pesticide Invention and Application, Nanjing 210095, China
| | - He Chen
- College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China; State & Local Joint Engineering Research Center of Green Pesticide Invention and Application, Nanjing 210095, China
| | - Xiude Hua
- College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China; State & Local Joint Engineering Research Center of Green Pesticide Invention and Application, Nanjing 210095, China.
| | - Minghua Wang
- College of Plant Protection, Nanjing Agricultural University, Nanjing 210095, China; State & Local Joint Engineering Research Center of Green Pesticide Invention and Application, Nanjing 210095, China
| |
Collapse
|
16
|
Morgenroth A, Jakel V, Hanke-Robinson H, Müller T, Freuling C, Cussler K, Duchow K, Krämer B, Bastian M. A novel electrophoretic immunoblot as antigen desorption and quantification method for alum-adjuvanted veterinary rabies vaccines. Vaccine 2020; 38:4281-4287. [PMID: 32402753 DOI: 10.1016/j.vaccine.2020.04.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 04/16/2020] [Accepted: 04/18/2020] [Indexed: 12/12/2022]
Abstract
Rabies vaccines for domestic animals are adjuvanted with aluminum salts. A particular challenge for in-vitro batch potency tests with these products is the fact that the antigens are firmly adsorbed to the aluminum salt matrix and thus are not easily available for antigen quantification. In the current manuscript we describe a versatile technique to quantify antigens in aluminum adsorbed vaccine formulations. A combined electrophoretic desorption and blotting method is presented that transfers the antigens to a nitrocellulose membrane followed by an immunoblot quantification of the transferred rabies antigens. For the immunoblot a rabies G-protein specific, monoclonal antibody is used that by itself has neutralizing activity. This ensures that only relevant antigens are quantified. By comparing end products with non-adjuvanted in-process material it can be demonstrated that the antigens are quantitatively desorbed from the adjuvant matrix. Resuts of the new antigen quantification method were compared with the outcome of the serological batch potency test as described in the European Pharmacopoeia. It is demonstrated that the new antigen quantification method reveals relevant differences between experimental vaccine batches formulated with increasing antigen loads. This proves the broad detection range of the method. In general, the results show that this highly versatile technique can serve as an important component of a comprehensive consistency test strategy and may be applied in a modified form to any alum-adjuvanted vaccine.
Collapse
Affiliation(s)
- Anna Morgenroth
- Friedrich-Loeffler-Institut, Südufer 10, D-17493 Greifswald, Insel Riems, Germany
| | - Verena Jakel
- Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
| | | | - Thomas Müller
- Friedrich-Loeffler-Institut, Südufer 10, D-17493 Greifswald, Insel Riems, Germany
| | - Conrad Freuling
- Friedrich-Loeffler-Institut, Südufer 10, D-17493 Greifswald, Insel Riems, Germany
| | - Klaus Cussler
- Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
| | - Karin Duchow
- Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
| | - Beate Krämer
- Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
| | - Max Bastian
- Friedrich-Loeffler-Institut, Südufer 10, D-17493 Greifswald, Insel Riems, Germany.
| |
Collapse
|
17
|
Wang X, gao Y, Yang Y, Liu Z, Gao L, Wu F, Yang X, Xu X, Wang Z, Sun S. Validation and evaluation of a newly developed time-resolved fluoroimmunoassay for cyclosporine quantitative analysis in human whole blood. J Pharm Biomed Anal 2020; 177:112890. [DOI: 10.1016/j.jpba.2019.112890] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 08/20/2019] [Accepted: 09/20/2019] [Indexed: 12/24/2022]
|